10-Q Filing

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC CIK: 1730430 Q1 2019

Filing Information

Form Type	10-Q
Accession Number	`0001558370-19-004284`
Period End Date	20190331
Filing Date	20190507
Fiscal Year	2019
Fiscal Period	Q1
XBRL Instance	knsa-20190331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 50 Income Statement 26 Cash Flow Statement 48 Stockholders Equity 16

Balance Sheet 50 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$71.98M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$82.63M	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	$243.90M	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	$235.33M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$8.42M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$6.45M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$313.75M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$334.96M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$6.19M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$6.36M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$3.35M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$3.68M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$210.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$210.00K	USD	Point-in-time
Deferred offering costs	`DeferredCosts`	$433.00K	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$1.22M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$1.46M	USD	Point-in-time
Total assets	`Assets`	$321.96M	USD	Point-in-time
Total assets	`Assets`	$346.16M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$6.89M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$10.92M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$15.62M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$16.42M	USD	Point-in-time
Accrued milestones	`AccruedMilestoneLiabilitiesCurrent`	$13.00M	USD	Point-in-time
Accrued milestones	`AccruedMilestoneLiabilitiesCurrent`	$15.00M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityCurrent`	$1.38M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$218.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$42.55M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$36.89M	USD	Point-in-time
Noncurrent operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$2.24M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$509.00K	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$144.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$42.70M	USD	Point-in-time
Total liabilities	`Liabilities`	$39.64M	USD	Point-in-time
Commitments and contingencies (Note 12)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 12)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$473.48M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$566.54M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.00K	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$8.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-260.05M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-194.22M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$279.27M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$-105.11M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$-89.71M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$306.52M	USD	Point-in-time
Total liabilities and shareholders equity	`LiabilitiesAndStockholdersEquity`	$346.16M	USD	Point-in-time
Total liabilities and shareholders equity	`LiabilitiesAndStockholdersEquity`	$321.96M	USD	Point-in-time

Income Statement 26 line items

Line Item	Tag	Value	Unit	Period
Research and development expense	`ResearchAndDevelopmentExpense`	$59.25M	USD	1 Quarter
Research and development expense	`ResearchAndDevelopmentExpense`	$12.63M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$3.71M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$8.39M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$16.34M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$67.65M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-16.34M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-67.65M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$1.81M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$305.00K	USD	1 Quarter
Loss before benefit for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-65.84M	USD	1 Quarter
Loss before benefit for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-16.04M	USD	1 Quarter
Benefit for income taxes	`IncomeTaxExpenseBenefit`	$-17.00K	USD	1 Quarter
Benefit for income taxes	`IncomeTaxExpenseBenefit`	$-53.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-15.98M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-65.82M	USD	1 Quarter
Net loss per share attributable to common shareholders - basic and diluted	`EarningsPerShareBasicAndDiluted`	$-1.27	USD	1 Quarter
Net loss per share attributable to common shareholders - basic and diluted	`EarningsPerShareBasicAndDiluted`	$-6.45	USD	1 Quarter
Weighted average common shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	2.48M	shares	1 Quarter
Weighted average common shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	51.76M	shares	1 Quarter
Net loss	`NetIncomeLoss`	$-15.98M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-65.82M	USD	1 Quarter
Unrealized gain on short-term investments	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$12.00K	USD	1 Quarter
Total other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$12.00K	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-15.98M	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-65.81M	USD	1 Quarter

Cash Flow Statement 48 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-15.98M	USD	1 Quarter
Net loss	`ProfitLoss`	$-65.82M	USD	1 Quarter
Depreciation expense	`Depreciation`	$471.00K	USD	1 Quarter
Depreciation expense	`Depreciation`	$8.00K	USD	1 Quarter
Share-based compensation expense	`ShareBasedCompensation`	$2.89M	USD	1 Quarter
Share-based compensation expense	`ShareBasedCompensation`	$558.00K	USD	1 Quarter
Class A common shares issued or to be issued as consideration for Primatope	`IssuanceOfStockForAcquisition`	$7.00M	USD	1 Quarter
Loss on disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$-66.00K	USD	1 Quarter
Non-cash rent expense	`NonCashRentExpense`	$30.00K	USD	1 Quarter
Accretion of discounts on short-term investments	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$846.00K	USD	1 Quarter
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-140.00K	USD	1 Quarter
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-240.00K	USD	1 Quarter
Prepaid expenses, right-of-use assets and other assets	`IncreaseDecreaseInPrepaidExpenseRightOfUseAssetsAndOtherAssets`	$1.21M	USD	1 Quarter
Prepaid expenses, right-of-use assets and other assets	`IncreaseDecreaseInPrepaidExpenseRightOfUseAssetsAndOtherAssets`	$-204.00K	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$1.09M	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-3.34M	USD	1 Quarter
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-807.00K	USD	1 Quarter
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-376.00K	USD	1 Quarter
Accrued milestones	`IncreaseDecreaseInAccruedMilestone`	$-2.00M	USD	1 Quarter
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-293.00K	USD	1 Quarter
Other long-term liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$509.00K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-14.97M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-63.26M	USD	1 Quarter
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.56M	USD	1 Quarter
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$75.00K	USD	1 Quarter
Purchases of short-term investments	`PaymentsToAcquireShortTermInvestments`	$181.81M	USD	1 Quarter
Proceeds from the maturities of short-term investments	`ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments`	$174.09M	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-9.28M	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-75.00K	USD	1 Quarter
Payments of offering costs	`PaymentsOfStockIssuanceCosts`	$100.00K	USD	1 Quarter
Payments of offering costs	`PaymentsOfStockIssuanceCosts`	$29.00K	USD	1 Quarter
Proceeds from exercise of options and employee share purchase plan	`ProceedsFromStockOptionsExercised`	$17.00K	USD	1 Quarter
Proceeds from exercise of options and employee share purchase plan	`ProceedsFromStockOptionsExercised`	$181.00K	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$83.19M	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$190.81M	USD	1 Quarter
Net increase in cash and cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$175.76M	USD	1 Quarter
Net increase in cash and cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$10.65M	USD	1 Quarter
Cash and cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$45.66M	USD	Point-in-time
Cash and cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$72.19M	USD	Point-in-time
Cash and cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$221.42M	USD	Point-in-time
Cash and cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$82.84M	USD	Point-in-time
Cash and cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$45.66M	USD	Point-in-time
Cash and cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$72.19M	USD	Point-in-time
Cash and cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$221.42M	USD	Point-in-time
Cash and cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$82.84M	USD	Point-in-time
Deferred offering costs included in accrued expenses and accounts payable	`DeferredOfferingCostsIncludedInAccruedExpensesAndAccountsPayable`	$1.58M	USD	1 Quarter
Deferred offering costs included in accrued expenses and accounts payable	`DeferredOfferingCostsIncludedInAccruedExpensesAndAccountsPayable`	$19.00K	USD	1 Quarter
Property and equipment included in accrued expenses and accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$37.00K	USD	1 Quarter

Stockholders Equity 16 line items

Line Item	Tag	Value	Unit	Period
Balance at the beginning of the period	`StockholdersEquity`	$279.27M	USD	Point-in-time
Balance at the beginning of the period	`StockholdersEquity`	$-105.11M	USD	Point-in-time
Balance at the beginning of the period	`StockholdersEquity`	$-89.71M	USD	Point-in-time
Balance at the beginning of the period	`StockholdersEquity`	$306.52M	USD	Point-in-time
Common shares issued or to be issued in connection with the acquisition of all issued and outstanding equity securities of Primatope Therapeutics, Inc.	`StockIssuedDuringPeriodValueAcquisitions`	$7.00M	USD	1 Quarter
Exercise of options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$17.00K	USD	1 Quarter
Exercise of options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$181.00K	USD	1 Quarter
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$2.89M	USD	1 Quarter
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$558.00K	USD	1 Quarter
Unrealized gain on short-term investments	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$12.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-15.98M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-65.82M	USD	1 Quarter
Balance at the end of the period	`StockholdersEquity`	$279.27M	USD	Point-in-time
Balance at the end of the period	`StockholdersEquity`	$-105.11M	USD	Point-in-time
Balance at the end of the period	`StockholdersEquity`	$-89.71M	USD	Point-in-time
Balance at the end of the period	`StockholdersEquity`	$306.52M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.